
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)*

Werewolf Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

95075A107

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 95075A107

Names of Reporting Persons

1

Longwood Fund III GP, LLC

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

		Sole Voting Power
	5	
		0.00
Number of Shares		Shared Voting Power
Beneficially Owned by Each Reporting Person	6	
		1,677,082.00
		Sole Dispositive Power
	7	
		0.00
With:		Shared Dispositive Power
	8	
		1,677,082.00
	9	Aggregate Amount Beneficially Owned by Each Reporting Person
		1,677,082.00
	10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
		<input type="checkbox"/>
	11	Percent of class represented by amount in row (9)
		3.5 %
	12	Type of Reporting Person (See Instructions)
		OO

Comment for Type of Reporting Person: (1) All such shares are held of record by Longwood III (as defined in Item 2(a) below). Longwood III GP (as defined in Item 2(a) below) is the general partner of Longwood III and may be deemed to share voting and dispositive power with respect to these securities. (2) Based on 48,540,200 shares of the Issuer's Common Stock outstanding as of October 29, 2025, as reported by the Issuer's in its Form 10-Q for quarter ended September 30, 2025, filed with the United States Securities and Exchange Commission (the "SEC") on November 4, 2025 (the "Form 10-Q").

SCHEDULE 13G

CUSIP No. 95075A107

		Names of Reporting Persons
1		Longwood Fund III, L.P.
		Check the appropriate box if a member of a Group (see instructions)
2		<input type="checkbox"/> (a)
		<input type="checkbox"/> (b)
3		Sec Use Only
		Citizenship or Place of Organization
4		DELAWARE
		Sole Voting Power
	5	
		0.00
Number of Shares		Shared Voting Power
Beneficially Owned by Each Reporting Person	6	
		1,677,082.00
		Sole Dispositive Power
	7	
		0.00
With:		Shared Dispositive Power
	8	
		1,677,082.00

9 Aggregate Amount Beneficially Owned by Each Reporting Person
1,677,082.00
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

11 Percent of class represented by amount in row (9)
3.5 %

12 Type of Reporting Person (See Instructions)
PN

Comment for Type of Reporting Person: (1) All such shares are held of record by Longwood III. Longwood III GP is the general partner of Longwood III and may be deemed to share voting and dispositive power with respect to these securities. (2) Based on 48,540,200 shares of the Issuer's Common Stock outstanding as of October 29, 2025, as reported by the Issuer in the Form 10-Q.

SCHEDULE 13G

Item 1.

Name of issuer:

(a) Werewolf Therapeutics, Inc.

Address of issuer's principal executive offices:

(b) 200 Talcott Avenue, Floor 2, Watertown, MA 02472

Item 2.

Name of person filing:

(a) This Amendment No. 1 (this "Amendment") amends and supplements the Schedule 13G originally filed by Longwood Fund III, L.P. ("Longwood III") and Longwood Fund III GP, LLC ("Longwood III GP" and together with Longwood III, the "Reporting Persons") with the SEC on May 14, 2021 (the "Original 13G"). This Amendment is being filed by the Reporting Persons.

Address or principal business office or, if none, residence:

(b) The address of the principal business office of each Reporting Person is 800 Boylston Street, Suite 1715, Boston, MA 02199.

Citizenship:

(c) Longwood III GP is a limited liability company organized under the laws of the State of Delaware. Longwood III is a limited partnership organized under the laws of the State of Delaware.

Title of class of securities:

(d) Common Stock

CUSIP No.:

(e) 95075A107

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in

accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

- (k) Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

- (a) See Row 9 of the cover page for each Reporting Person and corresponding footnotes.
Percent of class:
- (b) See Row 11 of the cover page for each Reporting Person and corresponding footnotes. %
- (c) Number of shares as to which the person has:
- (i) Sole power to vote or to direct the vote:
See Row 5 of the cover page for each Reporting Person and corresponding footnotes.
- (ii) Shared power to vote or to direct the vote:
See Row 6 of the cover page for each Reporting Person and corresponding footnotes.
- (iii) Sole power to dispose or to direct the disposition of:
See Row 7 of the cover page for each Reporting Person and corresponding footnotes.
- (iv) Shared power to dispose or to direct the disposition of:
See Row 8 of the cover page for each Reporting Person and corresponding footnotes.

Item 5. Ownership of 5 Percent or Less of a Class.

Ownership of 5 percent or less of a class

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Longwood Fund III GP, LLC

Signature: /s/ Robert Hadfield

Name/Title: Robert Hadfield, General Counsel

Date: 02/11/2026

Longwood Fund III, L.P.

Signature: /s/ Robert Hadfield

Name/Title: Robert Hadfield, General Counsel of the Reporting Person's general partner

Date: 02/11/2026

Comments accompanying signature: *Signed pursuant to a Power of Attorney included herein as an Exhibit to this Schedule 13G.